Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
Treat-to-target in systemic lupus erythematosus:recommendations from an international task force.
Treat-to-target in systemic lupuserythematosus: overarching principles and bullet points SLEにおけるTreat-to-target:包括的指針と箇条書きリスト
▸ Overarching principle 1: The management ofsystemic lupus erythematosus (SLE) should be based on shared decisions betweenthe informed patient and her/his physician(s).
▸ Overarching principle 2: Treatment of SLEshould aim at ensuring long-term survival, preventing organ damage, and optimizinghealth-related quality-of-life, by controlling disease activity and minimisingcomorbidities and drug toxicity.
▸ Overarching principle 3: The management ofSLE requires an understanding of its many aspects and manifestations, which mayhave to be targeted in a multidisciplinary manner.
▸ Overarching principle 4: Patients with SLEneed regular long-term monitoring and review and/or adjustment of therapy.
1. The treatment target of SLE should beremission of systemic symptoms and organ manifestations or, where remissioncannot be reached, the lowest possible disease activity, measured by avalidated lupus activity index and/or by organ-specific markers.
2. Prevention of flares (especially severeflares) is a realistic target in SLE and should be a therapeutic goal.
3. It is not recommended that the treatmentin clinically asymptomatic patients be escalated based solely on stable orpersistent serological activity.
4. Since damage predicts subsequent damageand death, prevention of damage accrual should be a major therapeutic goal inSLE.
5. Factors negatively influencinghealth-related quality of life (HRQOL), such as fatigue, pain and depressionshould be addressed, in addition to control of disease activity and preventionof damage.
6. Early recognition and treatment of renalinvolvement in lupus patients is strongly recommended.
7. For lupus nephritis, following inductiontherapy, at least 3 years of immunosuppressive maintenance treatment isrecommended to optimise outcomes.
8. Lupus maintenance treatment should aim for the lowest glucocorticoid dosage needed to control disease, and ifpossible, glucocorticoids should be withdrawn completely.
9. Prevention and treatment ofantiphospholipid syndrome (APS)-related morbidity should be a therapeutic goalin SLE; therapeutic recommendations do not differ from those in primary APS.
10. Irrespective of the use of othertreatments, serious consideration should be given to the use of antimalarials.
11. Relevant therapies adjunctive to anyimmunomodulation should be considered to control comorbidity in SLE patients.
ps
↓SLEの緊急病態
↓執筆協力しております!